Allogeneic hematopoietic stem cell transplantation in a prior lung transplant recipient.
Allogeneic hematopoietic stem cell transplantation
Lung transplant
Myelodysplastic syndromes
Transplant tolerance
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
23
04
2020
accepted:
06
08
2020
revised:
22
07
2020
pubmed:
18
8
2020
medline:
26
11
2020
entrez:
18
8
2020
Statut:
ppublish
Résumé
Hematological diseases after solid organ transplant (SOT) are an emerging issue as the number of long-term SOT survivors increases. Expertise in managing patients requiring allogeneic hematopoietic stem cell transplantation (HSCT) after SOT from independent donors is needed; however, clinical reports of HSCT after SOT are limited, and the feasibility and risk are not well understood. In particular, HSCT in prior lung transplant recipients is thought to be complicated as the lung is immunologically distinct and is constantly exposed to the surrounding environment. Herein, we describe a case of successful HSCT in a patient with myelodysplastic syndromes who had previously received a lung transplant from a deceased donor for bronchiolitis obliterans syndrome. Reports about cases of HSCT after lung transplant are quite rare; thus, we discuss the mechanisms of immune tolerance through the clinical course of our case. This case suggests that HSCT after SOT can be considered a therapeutic option in cases where the transplanted organ is functionally retained and the hematological disease is in remission.
Identifiants
pubmed: 32803699
doi: 10.1007/s12185-020-02967-x
pii: 10.1007/s12185-020-02967-x
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
871-877Subventions
Organisme : KAKENHI
ID : 20K08753
Références
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
doi: 10.1182/blood-2016-03-643544
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.
doi: 10.1182/blood-2012-03-420489
Yamamoto H, Uchida N, Yuasa M, Kageyama K, Ota H, Kaji D, et al. A novel reduced-toxicity myeloablative conditioning regimen using full-dose busulfan, fludarabine, and melphalan for single cord blood transplantation provides durable engraftment and remission in nonremission myeloid malignancies. Biol Blood Marrow Transplant. 2016;22:1844–50.
doi: 10.1016/j.bbmt.2016.06.017
Basak GW, Wiktor-Jedrzejczak W, Labopin M, Schoemans H, Ljungman P, Kobbe G, et al. Allogeneic hematopoietic stem cell transplantation in solid organ transplant recipients: a retrospective, multicenter study of the EBMT. Am J Transplant. 2015;15:705–14.
doi: 10.1111/ajt.13017
Benvenuto LJ, Anderson MR, Arcasoy SM. New frontiers in immunosuppression. J Thorac Dis. 2018;10:3141–55.
doi: 10.21037/jtd.2018.04.79
Ju L, Suberbielle C, Li X, Mooney N, Charron D. HLA and lung transplantation Front Med. 2019;13:298–313.
pubmed: 29974325
Alho AC, Kim HT, Chammas MJ, Reynolds CG, Matos TR, Forcade E, et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016;127:646–57.
doi: 10.1182/blood-2015-10-672345
Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009;113:3865–74.
doi: 10.1182/blood-2008-09-177840
Theilgaard-Mönch K, Raaschou-Jensen K, Palm H, Schjødt K, Heilmann C, Vindeløv L, et al. Flow cytometric assessment of lymphocyte subsets, lymphoid progenitors, and hematopoietic stem cells in allogeneic stem cell grafts. Bone Marrow Transplant. 2001;28:1073–82.
doi: 10.1038/sj.bmt.1703270
Kawakita T. Graft-versus-host disease after cord blood transplantation. Rinsho Ketsueki. 2013;54:607–16.
pubmed: 23912343
Kim YJ, Broxmeyer HE. Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance. Crit Rev Oncol Hematol. 2011;79:112–26.
doi: 10.1016/j.critrevonc.2010.07.009
Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:3447–544.
doi: 10.1200/JCO.2005.09.117
Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus host disease biology and therapy. Nat Rev Immunol. 2012;12:443–58.
doi: 10.1038/nri3212
Nakasone H, Tabuchi K, Uchida N, Ohno Y, Matsuhashi Y, Takahashi S, et al. Which is more important for the selection of cord blood units for haematopoietic cell transplantation: the number of CD34-positive cells or total nucleated cells? Br J Haematol. 2019;185:166–9.
doi: 10.1111/bjh.15418
Snyder LD, Wang Z, Chen DF, Reinsmoen NL, Finlen-Copeland CA, Davis WA, et al. Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. Chest. 2013;144:226–33.
doi: 10.1378/chest.12-0587
Wu B, Ingersoll K, Jug R, Yang LH, Luedke C, Lo A, et al. Myeloid neoplasms following solid organ transplantation: clinicopathologic studies of 23 cases. Am J Clin Pathol. 2017;149:55–66.
doi: 10.1093/ajcp/aqx133
Morton LM, Gibson TM, Clarke CA, Lynch CF, Anderson LA, Pfeiffer R, et al. Risk of myeloid neoplasms after solid organ transplantation. Leukemia. 2014;28:2317–23.
doi: 10.1038/leu.2014.132